Cantor Fitzgerald Has Weak Forecast for ACRS FY2025 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities researchers at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for Aclaris Therapeutics in a research report issued on Tuesday, March 18th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biotechnology company will post earnings per share of ($0.62) for the year, down from their prior forecast of ($0.54). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share.

Several other analysts have also commented on the stock. StockNews.com lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 8th. HC Wainwright upgraded Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Monday, December 23rd. Finally, Scotiabank assumed coverage on Aclaris Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $11.67.

Aclaris Therapeutics Trading Up 1.9 %

Shares of NASDAQ ACRS opened at $1.60 on Thursday. The stock has a market cap of $172.67 million, a price-to-earnings ratio of -3.08 and a beta of 0.48. The company’s 50-day moving average price is $2.16 and its 200 day moving average price is $2.20. Aclaris Therapeutics has a 52 week low of $0.95 and a 52 week high of $5.17.

Institutional Trading of Aclaris Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. increased its stake in shares of Aclaris Therapeutics by 113.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company’s stock valued at $985,000 after acquiring an additional 211,585 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in Aclaris Therapeutics by 187.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock worth $382,000 after purchasing an additional 216,826 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Aclaris Therapeutics by 9.3% in the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock valued at $974,000 after purchasing an additional 72,309 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Aclaris Therapeutics during the 3rd quarter valued at $1,053,000. Finally, Peapod Lane Capital LLC acquired a new stake in shares of Aclaris Therapeutics during the 4th quarter worth $1,003,000. 98.34% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.